ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 171 filers reported holding ARRAY BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $6,235,000 | +7693.8% | 134,582 | +4001.9% | 0.12% | +3733.3% |
| Q1 2019 | $80,000 | -77.7% | 3,281 | -86.9% | 0.00% | -82.4% |
| Q4 2018 | $358,000 | -83.5% | 25,141 | -80.6% | 0.02% | -84.4% |
| Q2 2018 | $2,172,000 | +209.8% | 129,461 | +201.5% | 0.11% | +165.9% |
| Q1 2018 | $701,000 | +4023.5% | 42,932 | +3125.5% | 0.04% | +4000.0% |
| Q4 2017 | $17,000 | -89.1% | 1,331 | -89.5% | 0.00% | -88.9% |
| Q3 2017 | $156,000 | -71.7% | 12,647 | -80.8% | 0.01% | -74.3% |
| Q2 2017 | $551,000 | +257.8% | 65,807 | +281.2% | 0.04% | +218.2% |
| Q1 2017 | $154,000 | +294.9% | 17,265 | +292.4% | 0.01% | +266.7% |
| Q4 2016 | $39,000 | +14.7% | 4,400 | -61.8% | 0.00% | +50.0% |
| Q1 2016 | $34,000 | -88.2% | 11,531 | -81.7% | 0.00% | -86.7% |
| Q3 2015 | $287,000 | +165.7% | 63,035 | +321.6% | 0.02% | +200.0% |
| Q2 2015 | $108,000 | – | 14,952 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |